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mental scores or work productivity. Greater increases in pharmacy costs for the DTM 
cohort were partially offset by smaller increases in medical costs, resulting in similar 
total health care costs for DTM patients compared with controls.
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OBJECTIVES: To investigate the impact on medication adherence for patients with 
common chronic conditions who reach the Medicare Part D coverage gap versus those 
who do not. The study is unique because it included characteristics of Medicare Part-D 
enrollees that are typically not available in administrative databases. METHODS: A 
survey based on the Seniors’ Prescription Coverage, Use and Spending Survey and the 
Brief Medication Questionnaire was distributed to elderly persons seeking care at the 
pharmacies within the University of Arkansas for Medical Sciences Advanced Practice 
Network. Patients recruited were ≥65 years, enrolled in Medicare Part D in 2007 or 
2008, and had the following conditions: hypertension, hyperlipidemia, diabetes, 
asthma/COPD, or depression. Adherence was a composite measure based on responses 
to several questions asking if subjects skipped doses, took smaller doses or decided to 
not ﬁll at all. Logistic regression was run to evaluate the impact of being in coverage 
gap on medication adherence, adjusting for age, sex, race, income, and education 
levels. RESULTS: A total of 152 subjects (62% female, 44.1% greater than 75 years 
of age, and 92.7% white) completed the survey. A total of 44.7% reached coverage 
gap in 2007 or 2008 and 31.6% reported non-adherent. 45.4% had monthly income 
of $2000 or less and 34.2 had no college education. Subjects in the coverage gap were 
twice as likely to be non-adherent to medication regimen as compared to those not in 
the gap (adjusted odds ratio = 2.07, p-value = 0.051). CONCLUSIONS: There is likely 
signiﬁcant impact of falling in the coverage gap on medication adherence for the 
elderly, which may have adverse health consequences. Decision makers ought to be 
cognizant of these implications.
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OBJECTIVES: Patients with depression may not respond to ﬁrst-line antidepressant 
(AD) therapy. Treatment options include changing from one AD to another and 
augmenting AD treatment with another concurrent AD, a stimulant, a mood stabilizer, 
or a second generation antipsychotic (SGA). While treatment decisions are primarily 
based on clinical considerations, they may also be inﬂuenced by patient cost-sharing. 
This study examines the relationship between cost-sharing and the use of augmenta-
tion among depressed patients who are already ﬁlling prescriptions for AD treatment. 
METHODS: Patients aged 18–64 in employer-sponsored plans with a diagnosis of 
depression and at least one antidepressant prescription were found in the 2004–2008 
MarketScan Database. Twelve months of continuous medical and prescription cover-
age were required before and after the initial antidepressant prescription. Patients with 
certain psychiatric diagnoses (e.g., schizophrenia) were excluded, resulting in a sample 
of 48,865 patients. Logistic regression models estimated the probability of augmenta-
tion within 12 months as a function of a plan-level cost-sharing index for brand and 
generic antidepressant and augmentation medications, controlling for demographic 
and clinical characteristics. Results are reported as odds ratios (OR) and 95% conﬁ-
dence intervals (CI). RESULTS: A $10 increase in the cost-sharing index for all 
augmentation classes was associated with a 5% decrease in the odds of any augmenta-
tion (OR 0.947, 95% CI 0.916–0.979, N = 48,795). A $10 increase in the cost-sharing 
index for antidepressants was associated with a 6% decrease in the odds of augmenta-
tion with a second antidepressant (OR 0.939, 95% CI 0.902–0.977, N = 47,269). 
CONCLUSIONS: Prescription drug cost-sharing appears to inﬂuence the decision to 
augment AD treatment. Financial barriers may prevent patients from receiving addi-
tional care.
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OBJECTIVES: To examine, using nationally representative data, the impact of Medi-
care Part D on out-of-pocket-costs, emergency room visits, hospitalization, and 
general health among civilian non-institutionalized Medicare beneﬁciaries. 
METHODS: The primary data were from the Medical Expenditure Panel Survey 
(MEPS) panel 10 data, which included Medicare beneﬁciaries aged 65 and older in 
2005. Near elderly respondents in MEPS (aged 55 to 63 years old) in 2005 served as 
control subjects. Raw and adjusted difference-in-differences were used to identify the 
effects of Medicare Part D on Medicare beneﬁciaries in terms of out-of-pocket costs, 
emergency room visits, hospitalization, and general health according to a preference-
based summary score (SF-12 based utility scores). RESULTS: Controlling for secular 
trends, Medicare Part D prescription drug beneﬁt resulted in a 22% (95% CI: 
7%–37%) reduction in out-of-pocket costs among Medicare beneﬁciaries (p = 
0.0020). However, the Medicare Part D beneﬁt did not signiﬁcantly impact emergency 
room visits (OR = 1.15, 95%CI: 0.59–1.71), hospitalization (OR = 1.64, 95% CI: 
0.68–2.60), or overall health (β = −0.0057, 95% CI: −0.0210–0.0096) among Medi-
care beneﬁciaries compared to controls. CONCLUSIONS: In the ﬁrst year following 
the implementation of Medicare Part D, out-of-pocket costs for prescription drugs 
were reduced among Medicare beneﬁciaries. However, Medicare Part D was not 
associated with improved health outcomes of Medicare beneﬁciaries as measured by 
reductions in emergency room visits and hospitalization and improvement in their 
health utility score. Further research should follow Medicare beneﬁciaries for a longer 
period of time after its implementation or focus on beneﬁciaries with diseases that 
might be more sensitive to Medicare Part D.
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OBJECTIVES: To compare the incremental medical expenditure associated with alter-
native disease modifying anti-rheumatoid drug (DMARDs) choices in Rheumatoid 
Arthritis. METHODS: Retrospective cohorts were constructed from California Med-
icaid paid insurance claims between January 1, 1998 to December 31, 2005. Non-
overlapping monthly panels were created from pharmacy claims for biologic 
(adalimumab and etanercept) and standard (methotrexate, leﬂuonomide, hydroxy-
chloroquine and sulfasalazine) DMARDs. Final sample included 59,788 observations 
on 7,025 patients. Covariates included age, gender, race, location of beneﬁciary’s 
county in either Northern or Southern California, population density in beneﬁciaries 
county, exclusive fee-for-service reimbursement used in beneﬁciary’s county, Medicare 
and Medicaid dual eligibility, Charlson comorbidities index excluding Rheumatoid 
arthritis, and expenditures associated with pharmacy, out-patient, inpatient, inpatient-
MD, LTC, and ER visits in the 3-months prior to treatment. We compared parameter 
estimates between naïve ﬁxed effects (FE) and instrumental variables based ﬁxed 
effects (IV-FE) panel data models. First lag of the observed treatment served as the 
instruments for the endogenous variables in IV-FE models to mitigate time-varying 
endogeneity. The primary dependant variable was total monthly expenditure. Second-
ary analysis included monthly expenditures associated with pharmacy, out-patient, 
inpatient, inpatient-MD, LTC, and ER visits. RESULTS: Based on the FE model, as 
compared to methotrexate, incremental monthly total expenditure associated with 
adalimumab ($1623.4, p < 0.001), etanercept ($1185.3, p < 0.001) and leﬂunomide 
($467.3, p < 0.001) was signiﬁcantly higher. Based on the IV-FE model, total expen-
diture associated with adalimumab ($2129.9, p < 0.001), etanercept ($1604.1, p < 
0.001) and leﬂunomide ($686.8, p < 0.001) exhibited signiﬁcant increase in magnitude 
of the parameter estimates, again with baseline as methotrexate. Under identiﬁcation 
test based on Anderson’s canonical correlation LM statistic, strongly rejected the null 
hypothesis in all the IV-FE models. CONCLUSIONS: The incremental acquisition cost 
associated with adalimumab, etanercept and leﬂunomide may not be offset by com-
mensurate reductions in routine and catastrophic resource utilization in the California 
Medicaid population.
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OBJECTIVES: Propensity scores (PS) are often used with the binary treatments. 
However, in day to day practice multiple treatment settings are experienced rather 
than binary treatments. Therefore extension of binary PS analysis to multiple PS will 
add to the empirical knowledge of use of PS. We compared binary PS analysis with 
multiple PS approach by examining clinical effectiveness in patients with Chronic 
Heart Failure (CHF). METHODS: The study was a retrospective analysis of a national 
cohort of patients diagnosed with CHF identiﬁed from the Department of Veterans 
Affairs electronic medical records system. PS analysis (binary and multiple) was used 
to balance 47 baseline patient characteristics between the different Angiotensin Con-
verting Enzyme Inhibitors (ACEIs). For multiple PS we used multinomial logistic 
regression and for binary PS we split our cohort into separate models. Effect of dif-
ferent ACEIs on time to death was assessed using a multiple PS weighted Cox pro-
portional hazard model and three separate binary PS weighted Cox proportional 
hazard models. Captopril was used as reference in all models. The statistical signiﬁ-
cance of effect of individual ACEIs on mortality was compared between the two 
propensity approaches. RESULTS: For binary propensity approach the adjusted 
hazards ratio from three different PS-weighted Cox models were 1.003 (95% CI: 
0.724–1.390) for enalapril, 0.740 (95% CI: 0.688–0.796) for fosinopril and 0.823 
(95% CI: 0.770–0.879) for lisinopril compared with captopril. For multiple propensity 
approach the adjusted hazards ratio were 1.033 (95% CI 0.739–1.445) for enalapril, 
0.738 (95% CI: 0.685–0.796) for fosinopril, and 0.819 (95% CI: 0.767–0.875) for 
lisinopril. CONCLUSIONS: We found the 2 propensity approaches produced similar 
